Brief: Vertex Announces European Commission Approval Of ALYFTREK, A New Once-Daily CFTR Modulator For The Treatment Of Cystic Fibrosis
01/07/2025 12:35
July 1 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES EUROPEAN COMMISSION APPROVAL OF ALYFTREK®, A NEW ONCE-DAILY CFTR MODULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS VERTEX PHARMACEUTICALS INC - ALYFTREK APPROVED FOR CF PATIENTS 6 YEARS AND OLDER IN EU VERTEX PHARMACEUTICALS INC - ALYFTREK TO BE AVAILABLE IN IRELAND, DENMARK, AND GERMANY Source text: ID:nBw4DS3z4a Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31